Coherus Oncology (CHRS) Income from Non-Controlling Interests (2014 - 2018)

Coherus Oncology has disclosed Income from Non-Controlling Interests across 5 years of filings, most recently posting -$18000.0 for Q3 2018.

• Income from Non-Controlling Interests for Q3 2018 came in at -$18000.0, down 350.0% year-over-year; the trailing twelve-month figure through Jun 2019 was -$18000.0 (up 68.97% YoY), and the FY2018 annual result was -$70000.0, up 39.66% from the prior year.
• Income from Non-Controlling Interests came in at -$18000.0 for Q3 2018 at Coherus Oncology, up from -$47000.0 in the prior quarter.
• In the past five years, Income from Non-Controlling Interests ranged from a high of $111000.0 in Q4 2014 to a low of -$224000.0 in Q2 2015.
• The 5-year median for Income from Non-Controlling Interests is -$56500.0 (2017), against an average of -$75500.0.
• Across the five-year window, Income from Non-Controlling Interests surged 95.79% in 2017 and slumped 350.0% in 2018, its largest moves.
• Coherus Oncology's Income from Non-Controlling Interests stood at $111000.0 in 2014, then slumped by 270.27% to -$189000.0 in 2015, then soared by 87.83% to -$23000.0 in 2016, then soared by 91.3% to -$2000.0 in 2017, then sank by 800.0% to -$18000.0 in 2018.
• The last three Income from Non-Controlling Interests figures came in at -$18000.0 (Q3 2018), -$47000.0 (Q2 2018), and -$5000.0 (Q1 2018), per Business Quant data.